PfCyRPA bound to monoclonal antibody Cy.007 Fab fragment

Heterotypic interactions drive antibody synergy against a malaria vaccine candidate.

DSRHVFIRTELSFIKNNVPCIRDMFFIYKRELYNICLDDLKGEEDETHIYVQKKVKDSWITLNDLFKETDLTGRPHIFAY
VDVEEIIILLCEDEEFSNRKKDMTCHRFYSNDGKEYNNAEITISDYILKDKLLSSYVSLPLKIENREYFLICGVSPYKFK
DDNKKDDILCMASHDKGETWGTKIVIKYDNYKLGVQYFFLRPYISKNDLSFHFYVGDNINNVKNVNFIECTHEKDLEFVC
SNRDFLKDNKVLQDVSTLNDEYIVSYGNDNNFAECYIFFNNENSILIKPEKYGNTAAGCYGGTFVKIDENRALFIYSSSQ
GIYNIHTIYYANYEGGGGSEPEA

PIRAVTLDESGGGLQTPGGTLSLVCKGSGFTFSSYEMQWVRQAPGKGLEWVADICIGGSYTGYGPAVKGRATISRDDGQS
TVRLQLNNLRAEDTGTYYCAKTARSDYCITGLDDIDAWGHGTEVIVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK

ALTQPSSVSANPGETVKITCSGGSSDYGWYQQKSPGSAPVTVIYENNKRPSDIPSRFSGSKFGSTHTLTITGVQADDEAV
YFCGSRDTNNGAFGAGTTLTVLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

0.2 M zinc acetate, 10 % PEG 3000, 0.1 M sodium acetate pH 4.5

malaria, Plasmodium falciparum, monoclonal antibody, vaccine, IMMUNE SYSTEM

DSRHVFIRTELSFIKNNVPCIRDMFFIYKRELYNICLDDLKGEEDETHIYVQKKVKDSWITLNDLFKETDLTGRPHIFAY
VDVEEIIILLCEDEEFSNRKKDMTCHRFYSNDGKEYNNSEITISDYILKDKLLSSYVSLPLKIENREYFLICGVSPYKFK
DDNKKDDILCMASHDKGETWGTKIVIKYDNYKLGVQYFFLRPYISKNDLSFHFYVGDNINNVKNVNFIECTHEKDLEFVC
SNRDFLKDNKVLQDVSTLNDEYIVSYGNDNNFAECYIFFNNENSILIKPEKYGNTTAGCYGGTFVKIDENRTLFIYSSSQ
GIYNIHTIYYANYE